Several technologies being developed in ATTRACT projects may help fight Covid-19. ATTRACT researchers are exploring their technologies to see how they can be used for early diagnosis and treatment of Covid-19.
AquAffirm launches eChem-Goldtm thin-film planar gold electrodes for Covid-19 biosensor research
AquAffirm, an ATTRACT project awardee for the VL4BD and DetectION projects, has launched a range of thin-film planar gold electrodes which are ideal for electrochemistry research associated with Covid-19 biosensor development.
AquAffirm’s thin-film planar gold electrodes are fabricated using high-resolution laser ablation of sputtered gold on a PET substrate with the cell volume delimited by screen-printed hydrophobic ink. Precision manufacture ensures excellent consistency and sensor-to-sensor reproducibility.
With the counter electrode, the working electrode and screen-printed reference electrode made of Ag/AgCl, these electrodes are designed for robust electrochemistry research, with excellent sensor-to-sensor reproducibility a key requirement.
“Together with biomedical/diagnostic applications, these electrodes are ideal for electrochemistry research and analysis in environmental, clinical or agri-food areas and for development of electrochemistry-based biosensors”
Commenting on the project launch, AquAffirm CEO Dr David Sarphie said: “We are delighted to be able to make these precision-manufactured electrodes available for researchers developing new sensors and tests for Covid-19. With the world in desperate need of more rapid, near-patient tests for both the coronavirus antigen and its associated antibodies, we believe these electrodes will prove a useful basis for academic groups and companies developing these tests.”
ABOUT ATTRACT: ATTRACT is a pioneering initiative bringing together Europe’s fundamental research and industrial communities to lead the next generation of detection and imaging technologies. Funded by the European Union’s Horizon 2020 programme, the ATTRACT project involves the European Organization for Nuclear Research (CERN), the European Molecular Biology Laboratory (EMBL), the European Southern Observatory (ESO), the European Synchrotron Radiation Facility (ESRF), the European XFEL, Institut Laue-Langevin (ILL), the European Industrial Research Management Association (EIRMA), Aalto University and Esade. More info at phase1.attract-eu.com